Ravi Thadhani

Dr Thadhani is an Independent Non Executive director of Orthocell who has co authored more than 300 scientific publications, including articles in medical journals. Dr Thadhani has more than 30 years as a general and physician, researcher, medical administrator and commercialisation adviser and has experience in patient care, advancing novel research programs, US regulatory pathways and commercialisation of devices and therapeutics. Dr Thadhani has served on US FDA advisory committees in the musculoskeletal, cardiovascular and renal sectors and has acted as expert advisor to global pharmaceutical companies including Sandoz, Shore, Novartis, Celgene, Bayer and Reata on clinical trial design, execution and data monitoring. He has also secured research funding from global US healthcare companies including Amgen, Abbott, Serono, Kaneka and Genzyme.